Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
triptan |
| gptkbp:approvalYear |
2002
|
| gptkbp:ATCCode |
N02CC06
|
| gptkbp:brand |
Relpax
|
| gptkbp:CASNumber |
143322-58-1
|
| gptkbp:chemicalClass |
indole derivative
|
| gptkbp:contraindication |
stroke
ischemic heart disease uncontrolled hypertension |
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:eliminationHalfLife |
4 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C22H26N2O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
eletriptan
|
| gptkbp:KEGGID |
D07913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
5-HT1B/1D receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
85%
|
| gptkbp:PubChem_CID |
CHEMBL1201312
119369 DB00218 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue dry mouth |
| gptkbp:synonym |
eletriptan hydrobromide
|
| gptkbp:UNII |
8Y164V895Y
|
| gptkbp:usedFor |
migraine
|
| gptkbp:bfsParent |
gptkb:triptans
|
| gptkbp:bfsLayer |
7
|